Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Treatment 2.0: catalysing the next phase of scale-up.

Hirnschall G, Schwartländer B.

Lancet. 2011 Jul 16;378(9787):209-11. doi: 10.1016/S0140-6736(11)60247-X. Epub 2011 Feb 25. No abstract available.

PMID:
21353697
2.

Battles with donors cloud Malawi's HIV prevention plan.

Donnelly J.

Lancet. 2011 Jul 16;378(9787):215-6. No abstract available.

PMID:
21770061
3.

The AIDS response catalysing economic and social transformation: the importance of local pharmaceutical production.

Sidibé M.

Antivir Ther. 2014;19 Suppl 3:3-4. doi: 10.3851/IMP2894. Epub 2014 Oct 13. No abstract available.

PMID:
25310132
4.

Trends in retention on antiretroviral therapy in national programs in low-income and middle-income countries.

Tassie JM, Baijal P, Vitoria MA, Alisalad A, Crowley SP, Souteyrand Y.

J Acquir Immune Defic Syndr. 2010 Aug;54(4):437-41. doi: 10.1097/QAI.0b013e3181d73e1b.

PMID:
20351559
5.

[Drugs for antiretroviral therapy. The costs of HAART].

Jablonowski H.

MMW Fortschr Med. 2008 Apr 28;150 Spec No 1:21. German. No abstract available.

PMID:
19024911
6.
7.

Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic.

Easterbrook PJ, Yu LM, Goetghebeur E, Boag F, McLean K, Gazzard B.

AIDS. 2000 Mar 31;14(5):561-71.

PMID:
10780719
8.

HIV/AIDS and the road to Rome.

[No authors listed]

Lancet. 2011 Jul 16;378(9787):199. doi: 10.1016/S0140-6736(11)61106-9. No abstract available.

PMID:
21763917
9.

British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals.

Brettle RP, Burns SB, Povey S, Leen CL, Welsby PD.

Lancet. 1997 Jun 21;349(9068):1837-8. No abstract available.

PMID:
9269232
10.

Science seals Mbeki/Msimang's AIDS ignominy.

Bateman C.

S Afr Med J. 2008 Nov;98(11):830, 832. No abstract available.

PMID:
19177883
11.

The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France.

Colin X, Lafuma A, Costagliola D, Lang JM, Guillon P.

Pharmacoeconomics. 2010;28 Suppl 1:59-68. doi: 10.2165/11587450-000000000-00000.

PMID:
21182344
12.

British HIV Association guidelines for antiretroviral treatment of HIV Seropositive individuals.

Harindra V.

Lancet. 1997 Jun 21;349(9068):1838. No abstract available.

PMID:
9269233
13.

Late presentation for HIV diagnosis and care in Germany.

Zoufaly A, an der Heiden M, Marcus U, Hoffmann C, Stellbrink H, Voss L, van Lunzen J, Hamouda O; ClinSurv Study Group.

HIV Med. 2012 Mar;13(3):172-81. doi: 10.1111/j.1468-1293.2011.00958.x. Epub 2011 Nov 7.

14.

Does alcohol intake affect highly active antiretroviral therapy (HAART) response in HIV-positive patients?

Fabris P, Tositti G, Manfrin V, Giordani MT, Vaglia A, Cattelan AM, Carlotto A.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):92-3. No abstract available.

PMID:
11064510
15.

Hope for South Africa--at last.

[No authors listed]

Lancet. 2003 Aug 16;362(9383):501. No abstract available.

PMID:
12932376
16.

Stirring the statistical pot.

Bateman C.

S Afr Med J. 2004 Mar;94(3):154-5. No abstract available.

17.

Antiretroviral therapy outcomes in resource-limited settings for HIV-infected children <5 years of age.

Sauvageot D, Schaefer M, Olson D, Pujades-Rodriguez M, O'Brien DP.

Pediatrics. 2010 May;125(5):e1039-47. doi: 10.1542/peds.2009-1062. Epub 2010 Apr 12.

PMID:
20385636
18.

Treatment as prevention--a double hat-trick.

Montaner JS.

Lancet. 2011 Jul 16;378(9787):208-9. doi: 10.1016/S0140-6736(11)60821-0. No abstract available.

PMID:
21763923
19.

British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals.

Carey PB, Lloyd J, Timmins D.

Lancet. 1997 Jun 21;349(9068):1837. No abstract available. Erratum in: Lancet 1997 Sep 13;350(9080):818.

PMID:
9269231
20.

Supplemental Content

Support Center